Archives
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Our synthetic approach to GPR antagonists was designed so th
2021-11-29

Our synthetic approach to GPR55 antagonists was designed so that many different structures could be accessed to rapidly explore initial SAR, along with validating or modifying our current model (). The synthesis begins with the coupling of a carboxylic Chymostatin to 4-piperidone by first forming t
-
Initial studies generally focused on the co administration
2021-11-29

Initial studies generally focused on the co-administration of glutamate with transport inhibitors and clearly revealed the ability of the blockers to exacerbate excitotoxic injury in both in vitro and in vivo models (McBean & Roberts, 1985, Robinson et al., 1993a). In addition to demonstrating the c
-
As glucagon stimulated hepatic glucose production is
2021-11-26

As glucagon-stimulated hepatic equol production is a key component of the normal response to hypoglycemia, the potential of a GCGr antagonist to delay or prevent recovery from a hypoglycemic state is a critical safety issue that must be addressed. Studies of the effects on time to recovery from a h
-
Otilonium Bromide In summary our findings provide the
2021-11-26

In summary, our findings provide the evidence and the mechanistic understanding of the protective effects of GIP receptor agonist, D-Ala2GIP, in the MPTP-induced neurotoxicity in mice. The observed protective effects are potentially due to reduced oxidative stress and attenuation of dopamine loss in
-
We tested formyl MYVKWPWYVWL which we had previously shown t
2021-11-26

We tested formyl-MYVKWPWYVWL, which we had previously shown to have essentially identical Kis for W190/N192, R190/K192 and R190/N190 [8] of 130 nM, for its ability to downregulate surface receptor (Fig. 5A). R190/K192 exhibited the lowest EC50 of 44±4 nM about 3 fold below the observed Ki and a maxi
-
Considering together the conformational docking and SAR resu
2021-11-26

Considering together the conformational, docking and SAR results of this and of previously published papers, a three points pharmacophore model can be developed considering the indispensable residues of SRSRY derived antagonists, namely Arg89, Arg91 and Tyr92. This model is shown in Fig. 10, and req
-
br Future perspectives A plethora of reports from in
2021-11-26

Future perspectives A plethora of reports from in vivo and in vitro human and animal studies have demonstrated the potential role of FGFR signalling in human carcinogenesis, whether it be in an oncogenic or tumour suppressive capacity. It is still not well understood how FGFRs can act as tumour s
-
Conformational analysis provides further insight into the SA
2021-11-26

Conformational analysis provides further insight into the SAR trends apparent in . Acyclic precursors – are 25–50-fold less active than their macrocyclic counterparts – against Pyk2. The global minima for – are conformations in which the –NHCH– linker between the pyrimidine and pyridine rings is sta
-
Histone modification is one of
2021-11-26

Histone modification is one of the major epigenetic mechanisms.8, 10 Specific histone modifications confer active or repressive transcriptional states. For instance, the trimethylation of Histone3-Lysine27 (H3K27me3) is a marker of tightly packaged heterochromatin and is associated with gene repress
-
br Conclusion In this research we have
2021-11-26

Conclusion In this research we have successfully formulated a PEGylated liposomal formulation encapsulating IRL-1620. The liposomal nanocarriers loaded with IRL-1620 were characterized for their particle size, PDI, zeta potential, and loading efficiency. We established that the treatment with IRL
-
Drosophila is a well established model to investigate the
2021-11-26

Drosophila is a well-established model to investigate the molecular and cellular defects underlying human neurodevelopmental disorders (Oortveld et al., 2013, van der Voet et al., 2014). Here, we establish Drosophila as a model for understanding the mechanisms linking mutations in KDM5 family protei
-
Although the presence of histamine secreting
2021-11-26

Although the presence of histamine-secreting bacteria has been well documented in foods, their presence within the human gut microbiota has not been investigated in detail. We recently performed an analysis of fecal samples from 161 volunteers to quantify the presence of bacterial HDC, using primers
-
In conclusion we demonstrate for
2021-11-26

In conclusion, we demonstrate, for the first time, that histamine plays a key role in regulating astrocyte function and gliotransmitter release, and we now must re-consider the roles of monoamine neurotransmitters in brain function in the context of astrocyte signalling. Further in vivo studies will
-
Cut proteins have five evolutionarily conserved
2021-11-26

Cut proteins have five evolutionarily conserved domains. These include a homeodomain, three Cut repeats, and a coiled coil structure. The cut repeats, called CR1, CR2, and CR3, are composed of 70 amino acids, and, along with the homeodomain, are each capable of binding DNA. Mammalian cut proteins f
-
Several studies have proposed that
2021-11-26

Several studies have proposed that high levels of KYNA in the AR-13324 contribute to cognitive dysfunctions presented by patients who suffer from schizophrenia [30], [31], [32], [33]. Considering that: (i) KYNA is a known GPR35 agonist [2], (ii) cognitive impairments in patients with schizophrenia
16097 records 537/1074 page Previous Next First page 上5页 536537538539540 下5页 Last page